Fibrinogen-Derived γ 377–395 Peptide Improves Cognitive Performance and Reduces Amyloid-β Deposition,without Altering Inflammation,in AβPP/PS1 Mice

Abstract

Abstract

Fibrinogen has emerged as a promising therapeutic target against Alzheimer’s disease because of its dual role in altered vascular function and amyloid-β aggregation. Here we provide evidence regarding cognitive improvement and reduction of brain parenchyma amyloid-β deposition in AβPP/PS1 mice after treatment for one month with the fibrinogen-blocking peptide Fibγ^377–395. No alteration in glial response or other neuroinflammatory markers was observed in the cortex of treated animals. Considering these results and the fact that Fibγ^377–395 does not affect coagulation function, this peptide could be considered as a promising and safe candidate for chronic treatment of Alzheimer’s disease.